Sanjiv Sam Gambhir, MD, PhD
Combined F18 and F18 FDG PET/CT for Evaluation of Malignancy
Contact Information
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Brief
Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. However, not all cancers are identified reliably due to variable rates of glucose metabolism. Sodium Fluorine-18 (F-18) was used in the 1970?s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. However, such an approach has the potential to improve cancer diagnosis, staging, prognosis, and therapy monitoring. The combination of these technologies may also allow for shorter imaging times, lower costs, as well as improved screening or earlier cancer detection. We will attempt a pilot study with 10 patients to acquire the preliminary results needed to proceed with additional 90 subjects.
Recruiting Status:
RecruitingStanford Recruiting Status:
RecruitingCondition(s):
Intervention(s):
Phase:
N/AEligibility
Ages Eligible for Study:
18 years to Any AgeGenders Eligible for Study:
Male and FemaleHealth of Volunteers:
People with the conditions listed in this trial can participate as controls.Key Inclusion Criteria:
a. Patients older than 18-year-old
b. Patients must be referred for a follow-up Tc-99m MDP bone scan. Their prior Tc-99m MDP bone scan must show at least 5 osseous lesions.
c. Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them.
Key Exclusion Criteria:
a. Patients who are not eligible for a Tc-99m MDP bone scan.
b. Patients who cannot complete a PET/CT scan.
c. Pregnant women.
d. Healthy volunteers.
e. Patients participating in other research studies.
The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.
Additional Study Details
Official Title:
Combined F18 and F18 FDG PET/CT for Evaluation of MalignancyAnticipated start date:
8/21/2007Lead Sponsor:
Stanford UniversityInvestigator(s):
Study Type:
ObservationalPurpose:
NOTNEEDEDDuration:
LongitudinalSelection:
Defined PopulationTiming:
ProspectiveTotal Number to be Enrolled:
100Total Number to be Enrolled at Stanford:
100More Information
Secondary ID(s):
- 1062330-100-DAADL
- 98043
- VAR0024
Locations & Contacts
Stanford Locations & Contacts:
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Non-Stanford Locations:
The Stanford website does not have any locations outside of Stanford listed for this trial. You may want to check clinicaltrials.gov for posible additional locations.
This listing was last updated:
8/18/2009PLEASE NOTE:
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician please feel free to call the SHC Physician Referral Service at (800) 756-9000 or send an email.
Help